Cannabis Science Inc (OTCMKTS:CBIS) is a penny play in the cannabinoid space that has started to garner tons of renewed attention as the stock launches up the chart. The company is ripping in response to headlines announcing that it has started work on its second 33,000 sq. ft. pilot cannabinoid drug development and manufacturing facility in Douglas County, Nevada.
“We have every intention of making 2017 the breakout year for our great company. To fast track our second pilot greenhouse and property build program, we ordered prefabricated and regular greenhouses. This second pilot property will house some of our grow operations and research and development activity. Our target is to begin growing a variety of prime strains in the first quarter of 2017,” said CEO Raymond C. Dabney. “We need all the drug development capacity we can get because we intend to ramp up our operations to meet the increased demand for cannabinoid medications across the country. This market is coming into full bloom, and 2017 is the year we will be positioned to capitalize on this tremendous opportunity.”
Cannabis Science Inc (OTCMKTS:CBIS) frames itself as a company that develops, produces, and commercializes phyto cannabinoid-based pharmaceutical products primarily in the United States. The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug. Cannabis Science, Inc. is based in Colorado Springs, Colorado. Cannabis Science Inc is a subsidiary of Weedmaps Media, Inc.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, the company is expanding its production facilities.
If there is one lesson we keep harping on time and time again throughout this post-election period for all stocks even remotely related to the cannabis business, it’s this: the market will reward investment.
There is an almost guarantee of a high ROI response from the market. That means, capital raises, new ground broken on projects for facilities, new leased space, new equipment. Anything that represents capital put to work to expand market share. It’s going to work. We’ve seen it with several stocks. CBIS is just another example.
The company’s announcement has been followed by 42% in gains in the past couple days.
As noted in the release, “the Douglas County, Nevada multi-phased project is the second pilot site and is currently in full buildout of greenhouses, water-well development, extraction points, and manufacturing. The grow operations at this site will support the extraction of cannabinoids for the development of key proprietary formulations. The site management team is in place, and the labor crew is being hired locally to create jobs and economic benefits to the community. This multi-phased facility is officially under construction.”
“The first quarter of 2017 will be an exciting time for more new product releases and much larger distribution channels. We will utilize various medication delivery methods (such as pills, creams, extracts, inhalers, tinctures, and balms) based on the ailment and we will release our cannabinoid-based medications across the country. I can’t emphasis enough what an exciting and busy year 2017 looks to be,” stated CBIS CEO Raymond C. Dabney.
Earning a current market cap value of $130.4M, CBIS has an extremely small store of cash on the books, which compares with an appreciable load ($2.41M) of total accumulated debt.
CBIS is making small coin at present, with trailing 12-month revenues coming in at 48.6k, with y/y top line declines. But the company is likely heading into a context more conducive to growth. This is not a story we love given the company’s penchant for dilution in the past. But this is hardly the right environment to be a bear on pot stocks. We will update this one again soon as developments transpire. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!